Close menu




February 3rd, 2026 | 07:15 CET

US government pours billions into USA Rare Earth - Could Antimony Resources be next?

  • Mining
  • antimony
  • CriticalMetals
  • Commodities
  • Investments
Photo credits: AI

Almonty Industries, MP Materials, and other commodity stocks have already demonstrated the new reality: in today's geopolitical environment, commodities are becoming critical, and stock prices can multiply dramatically. Antimony Resources offers investors an opportunity to participate at a comparatively early stage. History shows that when mining companies transition from explorer to producer, valuations can move into the billions. Despite a strong rally, Antimony Resources is still valued at "only" around EUR 50 million. Due to pressure from the US government and a mining-friendly jurisdiction, Antimony Resources could advance toward production significantly faster than is typical in the sector. A direct involvement by the US government would not be surprising. After investments in MP Materials, Vulcan Elements, and Trilogy Metals, the Trump administration recently pumped billions into USA Rare Earth. Could Antimony Resources be next?

time to read: 2 minutes | Author: Fabian Lorenz
ISIN: ANTIMONY RESOURCES CORP | CA0369271014

Table of contents:


    From niche metal to strategic factor

    Antimony has gone from being a niche metal to a strategic factor. This is precisely what Antimony Resources is benefiting from. In a recent interview with Lyndsay Malchuk of the International Investment Forum, Antimony Resources CEO Jim Atkinson emphasizes that defense, supply chains, and energy security have made the metal "critical." At the same time, North America has only limited control over its supply. With Bald Hill in New Brunswick, Canada, the company is developing a project in a mining-friendly jurisdiction that, according to Atkinson, explicitly promotes production. This tailwind is increasingly crucial, especially for critical raw materials.

    High-grade results

    Atkinson also reports on the latest results from Phase 2 drilling. In 2025, the company drilled more than 8,000 meters, bringing the total volume of drilling on the property to over 13,800 meters. The published grades are among the highest reported grades in North America to date. The company also aims to be "at the forefront" internationally. For Atkinson, consistency is more important than a single hit. In the first program, 75% to 80% of the drilling already yielded high-grade antimony. The second round follows a similar pattern. The goal now is to transition from exploration potential to a reliable resource. This will be achieved through a denser drill hole sequence and support from a consulting firm. Antimony Resources is planning a 10,000-meter program with a focus on "definition drilling" in the main area, but also intends to pursue two additional mineralized zones, including a newly discovered zone on the west side.

    https://youtu.be/6bjeA5Be2F0?si=tSxilHEv5C6Vvt04

    Efficient and fast production

    Compared to other projects, Atkinson believes Antimony Resources is better positioned, particularly in terms of capital requirements. His argument: high grade beats size. He points out that Bald Hill is significantly higher grade on average than known references in North America and could therefore start as a lean underground project. From this, he deduces potentially lower costs and faster feasibility. In addition, New Brunswick is working on a critical minerals strategy that is intended to shorten approval times. Environmental standards and the involvement of local communities would not be neglected in the process. According to Atkinson, Antimony Resources is preparing the approval process early and aims to submit the application at the end of 2026 or the beginning of 2027, with the goal of rapidly developing the project toward production.

    Conclusion: A highly attractive metal and equity opportunity

    Antimony is a highly compelling critical metal, alongside rare earths and tungsten. Antimony Resources is currently valued at around EUR 50 million, suggesting substantial upside potential. A potential entry by the US government is far from unlikely and would almost certainly act as a catalyst for further share price appreciation.

    Source: LSEG

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Lars Winter on October 13th, 2026 | 05:22 CEST

    BioNxt, CrowdStrike and Shell: Three exciting stocks ahead of the next price surge

    • Biotech
    • BioNxt Solutions
    • Crowdstrike
    • Shell
    • Crude Oil
    • Oil
    • Oil Price
    • Commodities
    • Biotechnology
    • Cyber Security
    • Cybersecurity

    On the stock market, facts matter most. New study results, strong figures and solid operational records tend to attract investor attention and often drive share prices higher. These three stocks deserve a closer look: BioNxt Solutions is approaching its first human study, CrowdStrike has reported a record quarter, and Shell is benefiting from exceptionally high refining margins. Three very different stocks, each offering opportunities alongside distinct risks. We take a closer look at these compelling names in our stock check.

    Read